Ceragenin shows strong activity against MRB strains of Pseudomonas

Ceragenix Pharmaceuticals, a US firm focused on infectious disease and dermatology says that researchers at the Eugene Appelbaum College of Pharmacy at the Wayne State University, in collaboration with JMI Laboratories and Paul Savage of Brigham Young University, have demonstrated in a series of in vitro experiments that an investigational drug compound known as CSA-13 shows rapid killing activity and synergistic activity with conventional antibiotics against multidrug resistant Pseudomonas aeuroginosa bacterial strains. P aeuroginosa is a leading cause of morbidity and mortality in patients with pneumonia and other respiratory diseases. The research appears ahead of print in the December